Cardiac CTA screening pays off if price is right
A cost-effectiveness study performed by Thomas Jefferson University researchers indicates cardiac CT angiography makes financial sense in nonemergent cases if the price is appropriate.
A cost-effectiveness study performed by Thomas Jefferson University researchers indicates cardiac CT angiography makes financial sense in nonemergent cases if the price is appropriate.
Outpatient standard angiography costs almost $2800, based on 2005 Medicare reimbursement rates. The scientific literature shows that about 10% to 30% of cardiac catheterizations in nonurgent cases are normal and, thus, unnecessary. CTA becomes a screening alternative to conventional catheter angiography when priced up to $270 or $810, reflecting the estimated lower and higher normalcy rates of 10% and 30%, respectively, according to Andrea Frangos, a research associate at Thomas Jefferson University in Philadelphia, Pennsylvania.
In addition to ruling out significant lesions, CTA can reveal findings that could save on extra treatment and hospitalization costs related to catheterization. Frangos presented a comparison of cardiac CTA with conventional catheter angiography in nonemergent patients at the 2006 American Roentgen Ray Society meeting in Vancouver.
Where Things Stand with the Radiologist Shortage
June 18th 2025A new report conveys the cumulative impact of ongoing challenges with radiologist residency positions, reimbursement, post-COVID-19 attrition rates and the aging of the population upon the persistent shortage of radiologists in the United States.
How to Successfully Launch a CCTA Program at Your Hospital or Practice
June 11th 2025Emphasizing increasing recognition of the capability of coronary computed tomography angiography (CCTA) for the evaluation of acute and stable chest pain, this author defuses common misperceptions and reviews key considerations for implementation of a CCTA program.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
